{"protocolSection":{"identificationModule":{"nctId":"NCT01998919","orgStudyIdInfo":{"id":"MO18633"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.","officialTitle":"A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)."},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-08"},"primaryCompletionDateStruct":{"date":"2011-11","type":"ACTUAL"},"completionDateStruct":{"date":"2011-11","type":"ACTUAL"},"studyFirstSubmitDate":"2013-11-25","studyFirstSubmitQcDate":"2013-11-25","studyFirstPostDateStruct":{"date":"2013-12-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-04-07","resultsFirstSubmitQcDate":"2014-07-07","resultsFirstPostDateStruct":{"date":"2014-07-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-12-12","lastUpdatePostDateStruct":{"date":"2015-01-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of sequential administration of Tarceva and gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer. Patients will be randomized to receive Tarceva (150 mg po) or placebo on days 15-28 of a 4 week cycle of intravenous platinum-based chemotherapy, for a total of 6 cycles. The anticipated time on study treatment is until disease progression or unacceptable toxicity."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":154,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tarceva + gemcitabine/platinum","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: gemcitabine","Drug: cisplatin","Drug: carboplatin"]},{"label":"Placebo + gemcitabine/platinum","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo","Drug: gemcitabine","Drug: cisplatin","Drug: carboplatin"]}],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily","armGroupLabels":["Tarceva + gemcitabine/platinum"]},{"type":"DRUG","name":"placebo","description":"orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application","armGroupLabels":["Placebo + gemcitabine/platinum"]},{"type":"DRUG","name":"gemcitabine","description":"1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles","armGroupLabels":["Placebo + gemcitabine/platinum","Tarceva + gemcitabine/platinum"]},{"type":"DRUG","name":"cisplatin","description":"75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin","armGroupLabels":["Placebo + gemcitabine/platinum","Tarceva + gemcitabine/platinum"]},{"type":"DRUG","name":"carboplatin","description":"5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin","armGroupLabels":["Placebo + gemcitabine/platinum","Tarceva + gemcitabine/platinum"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)","description":"Non-progression defined as documented best overall tumor response of complete response (CR), partial response (PR), or stable disease (SD; where SD was maintained for greater than \\[\\>\\]8 weeks) per RECIST. Investigator's assessment of response used in all analyses. CR equals (=)disappearance of all target lesions; PR=at least a 30 percent (%) decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference smallest sum LD since treatment started.","timeFrame":"Week 8"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Non-Progression at Week 16 as Assessed by RECIST","description":"Non-progression defined as documented best overall tumor response of CR, PR, or SD (where SD was maintained for \\>16 weeks) per RECIST.","timeFrame":"Week 16"},{"measure":"Percentage of Participants With Confirmed CR or PR as Assessed by RECIST","description":"CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases"},{"measure":"Duration of Response","description":"Duration of Response was defined similarly for complete responders and partial responders. CR was defined as the date CR was first recorded to the date on which PD was first noted or date of death. PR was defined as the date the first PR was recorded to the date of the first observation of PD or date of death.","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-study Phases"},{"measure":"Time to Progression","description":"Time to progression was defined as the interval between the day of randomization and the first documentation of PD. Participants who were withdrawn from the study without documented progression and for whom there exists CRF evidence that evaluations have been made, were censored at 1) the date of the last tumor assessment, 2) last date in the drug log, or 3) last date of follow-up when the participant was known to be progression free, whichever was last. Participants without post-baseline tumor assessments but known to be alive were censored at the time of randomization.","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the interval between the day of randomization and the date of first documentation of progressive disease or date of death, whichever came first.","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases"},{"measure":"Overall Survival","description":"Overall Survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.","timeFrame":"Date of randomization until date of death or date of last follow-up assessment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* histologically documented advanced or recurrent stage IIIB or IV non-small cell lung cancer;\n* measurable disease;\n* no previous chemotherapy for non-small cell lung cancer.\n\nExclusion Criteria:\n\n* unstable systemic disease;\n* any other malignancies in the last 5 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_CHAIR"}],"locations":[{"city":"Campbelltown","zip":"2560","country":"Australia","geoPoint":{"lat":-34.06667,"lon":150.81667}},{"city":"Camperdown","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"city":"Liverpool","zip":"2170","country":"Australia","geoPoint":{"lat":-33.91938,"lon":150.92588}},{"city":"Guangzhou","zip":"510060","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Jakarta","zip":"10410","country":"Indonesia","geoPoint":{"lat":-6.21462,"lon":106.84513}},{"city":"Jakarta","zip":"10430","country":"Indonesia","geoPoint":{"lat":-6.21462,"lon":106.84513}},{"city":"Semarang","zip":"50136","country":"Indonesia","geoPoint":{"lat":-6.99306,"lon":110.42083}},{"city":"Yogyakarta","zip":"55284","country":"Indonesia","geoPoint":{"lat":-7.80139,"lon":110.36472}},{"city":"Manila","zip":"1000","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"city":"Metro Manila","zip":"1502","country":"Philippines"},{"city":"Kyunggi-do","zip":"411-769","country":"South Korea"},{"city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, orally (PO), on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 milligrams per square meter (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 times \\[x\\] area under the serum concentration-time curve \\[AUC\\]), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"FG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"74"}]},{"type":"Randomized","achievements":[{"groupId":"FG000","comment":"1 participant randomized to erlotinib didn't receive study drug; analyzed in placebo for safety","numSubjects":"78"},{"groupId":"FG001","comment":"One participant withdrew consent prior to 1st dose and was excluded from safety analysis population.","numSubjects":"76"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"39"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"35"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full Analysis Set (FAS): all randomized participants. For analysis, participants were assigned the treatment group to which they were randomized, regardless of the treatment they actually received.","groups":[{"id":"BG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via intravenous (IV) infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"BG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"154"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.5","spread":"10.06"},{"groupId":"BG001","value":"56.4","spread":"10.43"},{"groupId":"BG002","value":"56.45","spread":"10.245"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"108"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)","description":"Non-progression defined as documented best overall tumor response of complete response (CR), partial response (PR), or stable disease (SD; where SD was maintained for greater than \\[\\>\\]8 weeks) per RECIST. Investigator's assessment of response used in all analyses. CR equals (=)disappearance of all target lesions; PR=at least a 30 percent (%) decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD; SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference smallest sum LD since treatment started.","populationDescription":"FAS; for analysis, participants were assigned the treatment group to which they were randomized, regardless of the treatment they actually received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","lowerLimit":"66.0","upperLimit":"85.7"},{"groupId":"OG001","value":"80.3","lowerLimit":"69.5","upperLimit":"88.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Mean Difference (Final Values)","paramValue":"3.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.3","ciUpperLimit":"17.0","estimateComment":"Approximate 95% CI for difference of two rates using Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-Progression at Week 16 as Assessed by RECIST","description":"Non-progression defined as documented best overall tumor response of CR, PR, or SD (where SD was maintained for \\>16 weeks) per RECIST.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Week 16","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","lowerLimit":"42.2","upperLimit":"65.2"},{"groupId":"OG001","value":"64.5","lowerLimit":"52.7","upperLimit":"75.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Mean Difference (Final Values)","paramValue":"10.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.6","ciUpperLimit":"26.8","estimateComment":"Approximate 95% CI for difference of two rates using Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With Confirmed CR or PR as Assessed by RECIST","description":"CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","lowerLimit":"15.3","upperLimit":"35.4"},{"groupId":"OG001","value":"36.8","lowerLimit":"26.1","upperLimit":"48.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Mean Difference (Final Values)","paramValue":"12.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.7","ciUpperLimit":"27.7","estimateComment":"Approximate 95% CI for difference of two rates using Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of Response was defined similarly for complete responders and partial responders. CR was defined as the date CR was first recorded to the date on which PD was first noted or date of death. PR was defined as the date the first PR was recorded to the date of the first observation of PD or date of death.","populationDescription":"FAS; only participants with CR or PR were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-study Phases","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"17","upperLimit":"33"},{"groupId":"OG001","value":"38.4","lowerLimit":"25","upperLimit":"77"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0075","statisticalMethod":"Log Rank"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0099","statisticalMethod":"Wald test","paramType":"Hazard Ratio (HR)","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.22","ciUpperLimit":"0.81"}]},{"type":"SECONDARY","title":"Time to Progression","description":"Time to progression was defined as the interval between the day of randomization and the first documentation of PD. Participants who were withdrawn from the study without documented progression and for whom there exists CRF evidence that evaluations have been made, were censored at 1) the date of the last tumor assessment, 2) last date in the drug log, or 3) last date of follow-up when the participant was known to be progression free, whichever was last. Participants without post-baseline tumor assessments but known to be alive were censored at the time of randomization.","populationDescription":"FAS Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"18","upperLimit":"28"},{"groupId":"OG001","value":"31.4","lowerLimit":"25","upperLimit":"36"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"Log Rank"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Wald Test","paramType":"Hazard Ratio (HR)","paramValue":"0.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.33","ciUpperLimit":"0.70"}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the interval between the day of randomization and the date of first documentation of progressive disease or date of death, whichever came first.","populationDescription":"FAS Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Screening/Baseline, Day 22 of Cycles 2, 4 and 6 and every 8 weeks in Post-Study and Off-Study Phases","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","lowerLimit":"17","upperLimit":"25"},{"groupId":"OG001","value":"30.4","lowerLimit":"24","upperLimit":"34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Log Rank"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Wald test","paramType":"Hazard Ratio (HR)","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.33","ciUpperLimit":"0.68"}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall Survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.","populationDescription":"FAS Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"Date of randomization until date of death or date of last follow-up assessment","groups":[{"id":"OG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily."},{"id":"OG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","lowerLimit":"60","upperLimit":"105"},{"groupId":"OG001","value":"74.1","lowerLimit":"49","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5991","statisticalMethod":"Log Rank"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3774","statisticalMethod":"Wald test","paramType":"Hazard Ratio (HR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.58","ciUpperLimit":"1.23"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events were recorded throughout primary and post-study treatment phases and for 28 days after last study dose.","description":"The Safety Analysis Population (SAP) included all participants who received at least 1 dose/infusion and had at least 1 post-baseline safety assessment. For analysis, participants were assigned to the treatment group of the first received dose irrespective of subsequent changes in treatment.","eventGroups":[{"id":"EG000","title":"Placebo Plus Chemotherapy","description":"Participants received placebo tablets, PO, on Days 15 to 28 of a 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive placebo tablets daily.","seriousNumAffected":17,"seriousNumAtRisk":79,"otherNumAffected":74,"otherNumAtRisk":79},{"id":"EG001","title":"Erlotinib Plus Chemotherapy","description":"Participants received erlotinib tablets, 150 mg per day, PO on Days 15 to 28 of every 4-week cycle; participants also received platinum-based doublet chemotherapy: gemcitabine 1250 mg/m\\^2 via IV infusion on Days 1 and 8 and either cisplatin (75 mg/m\\^2) or carboplatin (5 x AUC), via IV infusion, per investigator discretion, on Day 1. Participants received study drugs for a maximum of 6 cycles until disease progression, unacceptable toxicity or death. After 6 cycles, participants may have continued to receive erlotinib monotherapy, 150 mg daily.","seriousNumAffected":17,"seriousNumAtRisk":74,"otherNumAffected":73,"otherNumAtRisk":74}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Lower Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lymphangitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Renal Impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]}],"otherEvents":[{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":79},{"groupId":"EG001","numAffected":20,"numAtRisk":74}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":79},{"groupId":"EG001","numAffected":17,"numAtRisk":74}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":10,"numAtRisk":74}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":79},{"groupId":"EG001","numAffected":34,"numAtRisk":74}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":79},{"groupId":"EG001","numAffected":22,"numAtRisk":74}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":79},{"groupId":"EG001","numAffected":22,"numAtRisk":74}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":79},{"groupId":"EG001","numAffected":26,"numAtRisk":74}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":9,"numAtRisk":74}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":79},{"groupId":"EG001","numAffected":30,"numAtRisk":74}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":79},{"groupId":"EG001","numAffected":23,"numAtRisk":74}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":79},{"groupId":"EG001","numAffected":10,"numAtRisk":74}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":79},{"groupId":"EG001","numAffected":19,"numAtRisk":74}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":79},{"groupId":"EG001","numAffected":17,"numAtRisk":74}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":79},{"groupId":"EG001","numAffected":14,"numAtRisk":74}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":79},{"groupId":"EG001","numAffected":9,"numAtRisk":74}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":7,"numAtRisk":74}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":7,"numAtRisk":74}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":7,"numAtRisk":74}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":7,"numAtRisk":74}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":79},{"groupId":"EG001","numAffected":48,"numAtRisk":74}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":8,"numAtRisk":74}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":9,"numAtRisk":74}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"White blood cell count","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Neutrophil count","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Ear disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hepatic lesion","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Breast swelling","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Menstruation irregular","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Uterine haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Abnormal sensation in eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Meibomian gland dysfunction","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Vein pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nail infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Tinea infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Tinea versicolour","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Platelet count","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Haemoglobin","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Alanine aminotransferase","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Aspartate aminotransferase","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Blood creatinine abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Neutrophil percentage decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Sputum abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nasal dryness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pharyngeal ulceration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Respiratory tract haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Catheter site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dyshidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pruritus generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Glossitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Lip ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Parotid gland enlargement","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":79},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Tongue ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Tooth socket haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":79},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann- LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}